QMS Medical Allied Services (NSE:QMSMEDI) EBITDA: ₹269 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QMSMEDI QMS Medical Allied Services Ltd NSE:QMSMEDI
77 GF Score
Price ₹106.96
GF Value ₹120.61
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is QMS Medical Allied Services EBITDA?

QMS Medical Allied Services NSE:QMSMEDI -1.11% 77 EBITDA is ₹269 Mil as of Mar. 2026. GuruFocus rates NSE:QMSMEDI with a GF Score™ of 77/100 and a GF Value™ of ₹120.61 (Modestly Undervalued). The stock has 7 warning signs investors should review.

QMS Medical Allied Services's EBITDA for the three months ended in Mar. 2026 was ₹60 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹269 Mil.

During the past 12 months, the average EBITDA Growth Rate of QMS Medical Allied Services was -0.70% per year. During the past 3 years, the average EBITDA Growth Rate was 31.80% per year. During the past 5 years, the average EBITDA Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of QMS Medical Allied Services was 31.80% per year. The lowest was 3.50% per year. And the median was 11.10% per year.

QMS Medical Allied Services's EBITDA per Share for the three months ended in Mar. 2026 was ₹2.64. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹13.05.

During the past 12 months, the average EBITDA per Share Growth Rate of QMS Medical Allied Services was -7.30% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 19.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of QMS Medical Allied Services was 19.70% per year. The lowest was 3.50% per year. And the median was 10.15% per year.

QMS Medical Allied Services  (NSE:QMSMEDI) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


QMS Medical Allied Services EBITDA Related Terms


QMS Medical Allied Services EBITDA Historical Data

* Premium members only.

The historical data trend for QMS Medical Allied Services's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QMS Medical Allied Services EBITDA Chart

QMS Medical Allied Services Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial 177.43 117.76 188.02 271.23 269.31

QMS Medical Allied Services Quarterly Data
Mar20 Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.65 67.62 71.38 70.46 59.85

NSE:QMSMEDI vs ISRG, BDX, MDLN: EBITDA Comparison

For the Medical Instruments & Supplies subindustry, QMS Medical Allied Services's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QMS Medical Allied Services EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, QMS Medical Allied Services's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where QMS Medical Allied Services's EV-to-EBITDA falls into.


NSE:QMSMEDI
77GF Score
QMS Medical Allied Services Ltd NSE:QMSMEDI
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

QMS Medical Allied Services's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

QMS Medical Allied Services's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, QMS Medical Allied Services's EBITDA was ₹269 Mil.

QMS Medical Allied Services's EBITDA for the quarter that ended in Mar. 2026 is calculated as

QMS Medical Allied Services's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, QMS Medical Allied Services's EBITDA was ₹60 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹269 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of ₹269 Mil mean?
QMS Medical Allied Services (NSE:QMSMEDI) has a EBITDA of ₹269 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on QMS Medical Allied Services.
Is QMS Medical Allied Services' EBITDA too high?
QMS Medical Allied Services' current EBITDA is ₹269 Mil. Overall, QMS Medical Allied Services has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does QMS Medical Allied Services' EBITDA compare to ISRG and BDX?
QMS Medical Allied Services' EBITDA of ₹269 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on QMS Medical Allied Services. QMS Medical Allied Services's current EBITDA is ₹269 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QMS Medical Allied Services stock overvalued right now?
Based on GuruFocus' analysis, QMS Medical Allied Services (NSE:QMSMEDI) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹120.61, compared to a current price of ₹106.96 — trading 11.3% below its estimated fair value. The current EBITDA is ₹269 Mil. QMS Medical Allied Services' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For QMS Medical Allied Services (NSE:QMSMEDI), the current EBITDA is ₹269 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is QMS Medical Allied Services (NSE:QMSMEDI) Overvalued in 2026?

Based on GuruFocus' analysis, QMS Medical Allied Services stock appears to be undervalued. The current stock price of ₹106.96 is trading 11.3% below its estimated GF Value™ of ₹120.61. GuruFocus considers QMS Medical Allied Services to be Modestly Undervalued.

Key valuation signals for NSE:QMSMEDI:

  • EBITDA: ₹269 Mil
  • GF Value™: ₹120.61 vs. price of ₹106.96 (11.3% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the NSE:QMSMEDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


QMS Medical Allied Services Business Description

Address Prabhat Colony, Road No. 3, 1A-B/2A-B, Navkala Bharti Building, Plot No. 16, Near Santacruz Bus Depot, Santacruz (East), Mumbai, MH, IND, 400055
QMS Medical Allied Services Ltd is engaged in the marketing and distribution of a wide range of medical products as well as medical education services. The company's products are sold under brand name "QDevices" and also manage the distribution for other brands such as 3M, Heine, Rossmax and others. It offers medical products such as Blood Pressure Monitors, Glucose Monitoring Kits and strips, Dental Products, Personal protection kits eg-PPE kits, Infection prevention, Stethoscope and Oxygen Concentrator.
77GF Score

Get the complete analysis for NSE:QMSMEDI

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹106.96
Price
₹120.61
GF Value